What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
WHAT IS KNOWN AND OBJECTIVE: Abundant clinical data now confirm that ketamine produces a remarkable rapid-onset antidepressant effect - hours or days - in contrast to the delayed onset (typically weeks) of current antidepressant drugs. This surprising and revolutionary finding may lead to the development of life-saving pharmacotherapy for depressive illness by reducing the high suicide risk associated with the delayed onset of effect of current drugs. As ketamine has serious self-limiting drawbacks that restrict its widespread use for this purpose, a safer alternative is needed. Our objective is to review the proposed mechanism(s) of ketamine's rapid-onset antidepressant action for new insights into the physiological basis of depressive illness that may lead to new and novel targets for antidepressant drug discovery. METHODS: A search was conducted on published literature (e.g. PubMed) and Internet sources to identify information relevant to ketamine's rapid-acting antidepressant action and, specifically, to the possible mechanism(s) of this action. Key search words included 'ketamine', 'antidepressant', 'mechanism of action', 'depression' and 'rapid acting', either individually or in combination. Information was sought that would include less well-known, as well as well-known, basic pharmacologic properties of ketamine and that identified and evaluated the several hypotheses about ketamine's mechanism of antidepressant action. RESULTS: Whether the mechanistic explanation for ketamine's rapid-onset antidepressant action is related to its well-known antagonism of the NMDA (N-Methyl-d-aspartate) subtype of glutamate receptor or to something else has not yet been fully elucidated. The evidence from pharmacologic, medicinal chemistry, animal model and drug-discovery sources reveals a wide variety of postulated mechanisms. WHAT IS NEW AND CONCLUSION: The surprising discovery of ketamine's rapid-onset antidepressant effect is a game-changer for the understanding and treatment of depressive illness. There is some convergence on NMDA receptor antagonism as a likely, but to date unproven, common mechanism. The surprising number of other mechanisms, and the several novel biochemical aetiologies of depression proposed, suggests exciting new drug-discovery targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polanczyk, G. V., Salum, G. A., Sugaya, L. S., Caye, A., & Rohde, L. A. (2015) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12381 · Cited by 3,990
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“Ro 25-6981 ((aR,bS)-a-(4-hydroxyphenyl)b-methyl-4-(phenylmethyl)-1-piperidinepropanol maleate), an antagonist of an NMDA receptor subtype (GluN2B),(31) was shown to produce rapid (within 24 h) antidepressant effects in rats.(32) MK0657 (CERC-301), an orally bioavailable NMDA receptor 2B subtype antagonist (NR2B),(33)…”
BackgroundAndrade, L., Caraveo‐anduaga, J. J., Berglund, P., Bijl, R. V., Graaf, R. D., Vollebergh, W., Dragomirecka, E., Kohn, R., Keller, M., Kessler, R. C., et al. (2003) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.138 · Cited by 1,068 · cited 1×
“The prevalence rates for some countries, such as Japan, the Netherlands and Germany, are slightly lower (8%–12%).(3) For reasons not completely identified, the estimates for the United States are higher (18%).”
BackgroundZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 1×
“Infusions of Lanicemine (AZD6765), a novel low-affinity open-channel NMDA receptor blocker, produced an antidepressant effect within 3 days of administration, and in one trial within 80 min.(18) A randomized study of MK0657 (now CERC 301), an orally bioavailable NMDA receptor subtype antagonist, produced significant a…”
BackgroundBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632 · cited 1×
“It is one of the most widespread psychiatric illnesses, with an estimated prevalence of 10%–19% based on geographic location, differences in clinician diagnoses and reporting errors.(2) The prevalence rates for some countries, such as Japan, the Netherlands and Germany, are slightly lower (8%–12%).”
BackgroundSteiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568 · cited 2×
“Ketamine reduces IL-6 and TNF-alpha levels, slowing down cytokine-mediated deactivation of 5-HT and cytokine-mediated conversion of kynurenine into quinolinic acid.(63)”
BackgroundSignaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537
Overview of the Genetics of Major Depressive Disorder
Lohoff, F. W. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0150-6 · Cited by 498 · cited 1×
“The aetiology and clinical progression of MDD are multifactorial, including genetic and environmental influences.(7,8) The pathophysiology of MDD is still relatively poorly understood, but the historically prevailing theories derive from the monoamine hypothesis, and the majority of current pharmacotherapy targets a p…”
BackgroundKapur, S., & Seeman, P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001093 · Cited by 459
Research works printed but not linked: 37
- American Psychiatric Association, 2013, Diagnostic and statistical manual of mental disorders, 10.1176/appi.books.9780890425596 · DOI · Paper page
- Klein, 2013, Predictors of first lifetime onset of major depressive disorder in young adulthood, J Abnorm Psychol, 122, 1, 10.1037/a0029567 · DOI · Paper page
- Pasquini, 2014, Ethiopathogenesis of depressive disorders, Clin Pract Epidemiol Ment Health, 10, 166, 10.2174/1745017901410010166 · DOI
- O'Leary, 2015, Faster, better, stronger: towards new antidepressant therapeutic strategies, Eur J Pharmacol, 753, 32, 10.1016/j.ejphar.2014.07.046 · DOI
- Jarrett, 2008, How much cognitive therapy, for which patients, will prevent depressive relapse?, J Affect Disord, 111, 185, 10.1016/j.jad.2008.02.011 · DOI
- Segman, 1995, Onset and time course of antidepressant action: psychopharmacological implications of a controlled trial of electroconvulsive therapy, Psychopharmacology, 119, 440, 10.1007/BF02245860 · DOI
- Grözinger, 2015, On the significance of elektroconvulsive therapy in the treatment of severe mental diseases, Wien Klin Wochenschr, 127, 297, 10.1007/s00508-015-0749-z · DOI
- Drewniany, 2015, Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression, J Clin Pharm Ther, 40, 125, 10.1111/jcpt.12238 · DOI
- Dutta, 2015, Ketamine and other potential glutamate antidepressants, Psychia Res, 225, 1, 10.1016/j.psychres.2014.10.028 · DOI
- DeWilde, 2015, The promise of ketamine for treatment-resistant depression: current evidence and future directions, Ann N Y Acad Sci, 1345, 47, 10.1111/nyas.12646 · DOI · Paper page
- Preskorn, 2008, An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder, J Clin Psychopharmacol, 28, 631, 10.1097/JCP.0b013e31818a6cea · DOI · Paper page
- Lauterbach, 2011, Dextromethorphan as a potential rapid-acting antidepressant, Med Hypotheses, 76, 717, 10.1016/j.mehy.2011.02.003 · DOI
- Ates-Alagoz, 2013, NMDA receptor antagonists for treatment of depression, Pharmaceuticals (Basel), 6, 480, 10.3390/ph6040480 · DOI · Paper page
- Serafini, 2013, Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression, Curr Pharm Des, 19, 1898, 10.2174/13816128113199990293 · DOI · Paper page
- Pittenger, 2007, The NMDA receptor as a therapeutic target in major depressive disorder, CNS Neurol Disord Drug Targets, 6, 101, 10.2174/187152707780363267 · DOI · Paper page
- Zappettini, 2014, Nicotinic alpha7 receptor activation selectively potentiates the function of NMDA receptors in glutamatergic terminals of the nucleus accumbens, Front Cell Neurosci, 8, 332, 10.3389/fncel.2014.00332 · DOI
- Fernandes, 2015, Inhibition of in vivo [3H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice, Eur J Pharmacol, 766, 1, 10.1016/j.ejphar.2015.08.044 · DOI
- Yilmaz, 2011, Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model, J Membr Biol, 242, 145, 10.1007/s00232-011-9385-3 · DOI
- Taylor, 2008, Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy, J Psychopharmacol, 22, 473, 10.1177/0269881107081510 · DOI · Paper page
- Godlewska, 2014, Short-term escitalopram treatment and hippocampal volume, Psychopharmacology, 231, 4579, 10.1007/s00213-014-3771-3 · DOI
- Boyer, 1998, Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study, J Molec Neurosci, 10, 219, 10.1007/BF02761776 · DOI
- Nowak, 1998, Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors, Eur J Pharmacol, 342, 367, 10.1016/S0014-2999(97)01589-6 · DOI
- Muhonen, 2008, Treatment of alcohol dependence in patients with co-morbid major depressive disorder - predictors for the outcomes with memantine and escitalopram medication, Subst Abuse Treat Prev Policy, 3, 20, 10.1186/1747-597X-3-20 · DOI · Paper page
- Dietrich, 2000, Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial, Bipolar Disord, 2, 65, 10.1034/j.1399-5618.2000.020110.x · DOI · Paper page
- Stryjer, 2003, Amantadine as augmentation therapy in the management of treatment-resistant depression, Int Clin Psychopharmacol, 18, 93, 10.1097/00004850-200303000-00005 · DOI · Paper page
- Zarate, 2004, An open-label trial of riluzole in patients with treatment-resistant major depression, Am J Psychiatry, 161, 171, 10.1176/appi.ajp.161.1.171 · DOI · Paper page
- Sanacora, 2007, Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms, Biol Psychiatry, 61, 822, 10.1016/j.biopsych.2006.08.037 · DOI · Paper page
- Skolnick, 2015, Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test, Acta Neuropsychiatr, 27, 228, 10.1017/neu.2015.14 · DOI
- Preskorn, 2015, Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent, J Psychia Pract, 21, 140, 10.1097/01.pra.0000462606.17725.93 · DOI · Paper page
- Miller, 2013, Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression, Neuropsychopharmacology, 38, 1607, 10.1038/npp.2013.140 · DOI
- Russi, 1992, Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions, J Neurochem, 59, 2076, 10.1111/j.1471-4159.1992.tb10097.x · DOI · Paper page
- Stone, 2001, Kynurenines in the CNS: from endogenous obscurity to therapeutic importance, Prog Neurobiol, 64, 185, 10.1016/S0301-0082(00)00032-0 · DOI · Paper page
- Stone, 2002, Endogenous kynurenines as targets for drug discovery and development, Nat Rev Drug Discov, 1, 609, 10.1038/nrd870 · DOI · Paper page
- Connick, 1992, Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity, Gen Pharmacol, 23, 235, 10.1016/0306-3623(92)90017-E · DOI
- Yuhas, 2015, Immunomodulatory activity of ketamine in human astroglial A172 cells: possible relevance to its rapid antidepressant activity, J Neuroimmunol, 282, 33, 10.1016/j.jneuroim.2015.03.012 · DOI
- Mlyniec, 2015, Study of antidepressant drugs in GPR39 (zinc receptor(-)/(-)) knockout mice, showing no effect of conventional antidepressants, but effectiveness of NMDA antagonists, Behav Brain Res, 287, 135, 10.1016/j.bbr.2015.03.053 · DOI
- Coates, 2001, Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant α7 and α4β2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes, Br J Pharmacol, 134, 871, 10.1038/sj.bjp.0704315 · DOI · Paper page
Cited by
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0503-4 · Cited by 174
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2020) · Molecular Brain · doi:10.1186/s13041-020-00627-z · Cited by 85
Metadata
- Authors
- Strasburger, S. E., Bhimani, P. M., Kaabe, J. H., Krysiak, J. T., Nanchanatt, D. L., Nguyen, T. N., Pough, K. A., Prince, T. A., Ramsey, N. S., Savsani, K. H., Scandlen, L., Cavaretta, M. J., & Raffa, R. B.
- Venue
- Journal of Clinical Pharmacy and Therapeutics
- Publisher
- Wiley
- Published
- 2017-01-22
- Volume
- 42
- Issue
- 2
- Pages
- 147-154
- ISSN
- 0269-4727 (ISSN-L)
- OpenAlex
- W2579968803
- Cited by
- 84
- References
- 30
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1 (tdm)
- onlinelibrary.wiley.com/termsAndConditions (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. https://app.cochat.ai/papers/10.1111/jcpt.12497
- The paper
- Strasburger, S. E., Bhimani, P. M., Kaabe, J. H., Krysiak, J. T., Nanchanatt, D. L., Nguyen, T. N., Pough, K. A., Prince, T. A., Ramsey, N. S., Savsani, K. H., Scandlen, L., Cavaretta, M. J., & Raffa, R. B. (2017). What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1111/jcpt.12497
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.